Danaher Co. (NYSE:DHR) Position Trimmed by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans lowered its stake in shares of Danaher Co. (NYSE:DHR - Free Report) by 8.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 582,706 shares of the conglomerate's stock after selling 51,825 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.08% of Danaher worth $162,003,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in DHR. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the second quarter worth $25,000. nVerses Capital LLC bought a new stake in Danaher in the second quarter valued at $25,000. MFA Wealth Advisors LLC bought a new stake in Danaher in the second quarter valued at $51,000. Financial Connections Group Inc. bought a new stake in Danaher in the second quarter valued at $51,000. Finally, Western Pacific Wealth Management LP bought a new stake in Danaher in the first quarter valued at $55,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Trading Down 3.7 %

DHR traded down $8.88 during trading on Friday, reaching $230.50. The company had a trading volume of 5,435,775 shares, compared to its average volume of 3,011,640. The firm's 50-day simple moving average is $262.20 and its 200 day simple moving average is $260.57. The company has a market cap of $166.49 billion, a price-to-earnings ratio of 43.99, a PEG ratio of 4.24 and a beta of 0.85. Danaher Co. has a 12-month low of $206.30 and a 12-month high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts' consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion for the quarter, compared to analysts' expectations of $5.59 billion. Danaher had a return on equity of 10.62% and a net margin of 16.39%. Danaher's revenue was up 3.1% on a year-over-year basis. During the same quarter last year, the business posted $2.02 EPS. Equities research analysts anticipate that Danaher Co. will post 7.51 earnings per share for the current year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were paid a $0.27 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.47%. Danaher's dividend payout ratio is currently 20.61%.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares of the company's stock, valued at $1,130,374.44. The trade was a 18.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 11.10% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DHR. Wells Fargo & Company began coverage on Danaher in a research note on Tuesday, August 27th. They issued an "equal weight" rating and a $280.00 target price on the stock. Royal Bank of Canada cut their target price on Danaher from $333.00 to $311.00 and set an "outperform" rating on the stock in a research note on Wednesday, October 23rd. Stifel Nicolaus lifted their price objective on shares of Danaher from $250.00 to $265.00 and gave the company a "hold" rating in a research note on Wednesday, October 23rd. KeyCorp lifted their price objective on shares of Danaher from $290.00 to $310.00 and gave the company an "overweight" rating in a research note on Wednesday, October 23rd. Finally, The Goldman Sachs Group lifted their price objective on shares of Danaher from $225.00 to $250.00 and gave the company a "neutral" rating in a research note on Wednesday, July 24th. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat.com, Danaher has a consensus rating of "Moderate Buy" and an average target price of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.